Evaluating the use of dexmedetomidine in neurocritical care patients

Neurocritical Care

Volumn 12, Issue 3, 2010, Pages 356-361

  Grof, Tina M ^a   Bledsoe, Kathleen A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Adverse events; Analgesics; Dexmedetomidine; Intensive care unit; Sedatives

Indexed keywords

DEXMEDETOMIDINE; FENTANYL; MIDAZOLAM; PROPOFOL;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG DOSE TITRATION; DRUG TOLERABILITY; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; INFUSION RATE; INTENSIVE CARE UNIT; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RICHMOND AGITATION SEDATION SCALE; SCORING SYSTEM; SEDATION; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADRENERGIC ALPHA-AGONISTS; ADULT; AROUSAL; BLOOD PRESSURE; CONSCIOUS SEDATION; CRITICAL CARE; DEXMEDETOMIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HEMODYNAMICS; HUMANS; HYPNOTICS AND SEDATIVES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOMOTOR AGITATION; YOUNG ADULT;

EID: 77955093101     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12028-008-9156-x     Document Type: Article

References (11)

1. Bekker A, Sturaitis MK. Dexmedetomidine for neurological surgery. Neurosurgery. 2005;57(Suppl 1):1-10. doi:10.1227/01. NEU.0000163476.42034.A1.
2. Prielipp RC, Wall MH, Tobin JR, Groban L, Cannon MA, Fahey FH, et al. Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow. Anesth Analg. 2002;95:1052-1059 doi:10.1097/00000539- 200210000-00048.
3. Gerlach AT, Dasta JF. Dexmedetomidine: an updated review. Ann Pharmacother. 2007;41:245-254 doi:10.1345/aph.1H314. (Pubitemid 46340055)
4. Product Information. Precedex (dexmedetomidine). Lake Forest, IL: Hospira; April 2004.
5. Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30:2188-2196 doi:10.1007/s00134-004-2417-z. (Pubitemid 40174254)
6. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30(1):119-141 doi:10.1097/00003246-200201000-00020. (Pubitemid 34112188)
7. Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond agitation-sedation scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166:1338-1344 doi:10.1164/rccm.2107138. (Pubitemid 35292699)
8. Venn RM, Newman PJ, Grounds RM. A phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med. 2003;29:201-207
9. MacLaren R, Forrest LK, Kiser TH. Adjunctive dexmedetomidine therapy in the intensive care unit: a retrospective assessment of impact on sedative and analgesic requirements, levels of sedation and analgesia, and ventilatory and hemodynamic parameters. Pharmacotherapy. 2007;27(3):351-359 doi:10.1592/phco.27. 3.351. (Pubitemid 46327903)
10. Kim E. Agitation, aggression, and disinhibition syndromes after traumatic brain injury. NeuroRehabilitation. 2002;17:297-310.
11. Levy M, Berson A, Cook T, Bollegala N, Seto E, Turanski S, et al. Treatment of agitation following traumatic brain injury: a review of the literature. NeuroRehabilitation. 2005;20:279-306.